EytanMosheSteinMD

PubMed

• 1 citations
  How I treat acute myeloid leukemia with differentiation therapy.
  Ghayas C Issa, Eytan M Stein, Courtney D DiNardo
  Blood. 2025-03-20
• Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies.
  Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, Andrew Kuykendall, David Sallman
  Leukemia. 2025-03-01
• HMA/VEN treatment modifications and associated outcomes in-mutant AML.
  Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav K Gupta, P Dayand Borge
  Leukemia & Lymphoma. 2025-02-01

Journal Articles

• Disrupted Radial and Tibial Microarchitecture in Patients with Monoclonal Gammopathy of Undetermined Significance  
  E Shane, E M Stein, S Lentzsch, J Fu, Osteoporosis international
• Clonal Heterogeneity of Acute Myeloid Leukemia Treated with the IDH2 Inhibitor Enasidenib  
  Eytan Stein, MD, Nature
• Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface Mutations  
  Martin S Tallman, Eytan M Stein, Alan H Shih, Maria E Arcila, Andrew M Intlekofer, Craig B Thompson, Mikhail Roshal, Nature
• Abnormal Microarchitecture and Stiffness in Postmenopausal Women Using Chronic Inhaled Glucocorticoids  
  E Dimango, E Shane, E M Stein, Osteoporosis international
• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
• A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML  
  Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood
• Join now to see all

Abstracts/Posters

• Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of th...
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Anal...
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propen...
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosid...
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myelo...
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Use of Molecular Medicine to Assess Pretreatment Prognosis of Myeloid Disorders 
  ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
• Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Adult Clinical Malignant Hematology 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• AML with Mutations in IDH1 and DNMT3A Exhibits a Distinct Epigenetic Signature with Poorer Overall Survival 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Focus on AML: Clinical Practice Today 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute mye... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Enasidenib for Acute Myeloid Leukemia. FDA Approvals and Their Incorporation into Clinical Practice 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
• Join now to see all